ALTO-100 PO Tablet for Depression

Phase 2

Waitlist Available

Research Sponsored by Alto Neuroscience

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured at day 1, day 14, day 28, day 42, day 56

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying a new treatment called ALTO-100. It includes a wide range of participants and aims to understand how the treatment affects the body by collecting biological data.

Eligible Conditions

Depression

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured at day 1, day 14, day 28, day 42, day 56

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured at day 1, day 14, day 28, day 42, day 56

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at day 1, day 14, day 28, day 42, day 56 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100

Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100

To understand the relationship between baseline biology and score change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-100 from Screening to end of treatment

+1 more